Misiu - some of the things you said is your interpretation of the conf call.
I have listened to P conf calls for 3 years - he mixes thing up and so I do not think we have clear answer.
You think FDA will considering converting current trials based on 325-550 mg dosing - I do not believe that - simply based on my reading and investing in biotech. A variable dosing in P2b does not give FDA sufficient confidence to approve one dose out of 2 as final dose.
The fact that P is trying 700 mg - I think he wants to go for big kill - reach 80-85% range.
Also - I do not think P has started 700 mg dosing - I hope I am wrong.
So no harm in asking the questions - I don’t think we will get any answers.